Lenvatinib, Pembrolizumab, and TACE Demonstrate Significant Progression-Free Survival ...
Lenvatinib, pembrolizumab, and TACE significantly improved progression-free survival (PFS) for intermediate-stage hepatocellular carcinoma (HCC) patients compared to placebo and TACE, according to the phase 3 LEAP-012 study. Median PFS was 14.6 months vs. 10.0 months, with a hazard ratio of 0.66 (P = .0002). The treatment regimen showed manageable safety and no new concerns, suggesting it could be a new option for this patient group.
Related Clinical Trials
Reference News
Lenvatinib, pembrolizumab, and TACE significantly improved PFS in intermediate-stage HCC patients compared to placebo plus TACE in the LEAP-012 study, with manageable safety profiles.
Adding lenvatinib and pembrolizumab to TACE improved median PFS in intermediate-stage HCC from 10 to 14.6 months. Grade 3/4 TRAEs were more frequent but few patients discontinued treatment. LEAP-012 trial suggests this combination may be a new treatment option for intermediate-stage HCC.
Lenvatinib, pembrolizumab, and TACE significantly improved progression-free survival (PFS) for intermediate-stage hepatocellular carcinoma (HCC) patients compared to placebo and TACE, according to the phase 3 LEAP-012 study. Median PFS was 14.6 months vs. 10.0 months, with a hazard ratio of 0.66 (P = .0002). The treatment regimen showed manageable safety and no new concerns, suggesting it could be a new option for this patient group.
LEAP-012 trial showed improved PFS and ORR with lenvatinib, pembrolizumab, and TACE in intermediate-stage HCC, though OS data are still immature. The combination demonstrated a manageable safety profile, potentially making it a new standard of care.